Free Trial

Recursion Pharmaceuticals (RXRX) Competitors

Recursion Pharmaceuticals logo
$5.26 +0.05 (+0.96%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$5.18 -0.08 (-1.43%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RXRX vs. BPMC, BBIO, VRNA, ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, and LNTH

Should you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.

Recursion Pharmaceuticals vs. Its Competitors

Recursion Pharmaceuticals (NASDAQ:RXRX) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Recursion Pharmaceuticals presently has a consensus target price of $7.00, indicating a potential upside of 33.08%. Blueprint Medicines has a consensus target price of $128.06, indicating a potential downside of 0.16%. Given Recursion Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Recursion Pharmaceuticals is more favorable than Blueprint Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Recursion Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Blueprint Medicines
0 Sell rating(s)
17 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.27

In the previous week, Recursion Pharmaceuticals had 4 more articles in the media than Blueprint Medicines. MarketBeat recorded 9 mentions for Recursion Pharmaceuticals and 5 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 0.81 beat Recursion Pharmaceuticals' score of 0.54 indicating that Blueprint Medicines is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Recursion Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Blueprint Medicines
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 8.4% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 4.2% of Blueprint Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Blueprint Medicines has higher revenue and earnings than Recursion Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Recursion Pharmaceuticals$58.84M36.34-$463.66M-$1.77-2.97
Blueprint Medicines$508.82M16.28-$67.09M-$2.47-51.93

Recursion Pharmaceuticals has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500.

Blueprint Medicines has a net margin of -27.70% compared to Recursion Pharmaceuticals' net margin of -961.32%. Blueprint Medicines' return on equity of -64.60% beat Recursion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Recursion Pharmaceuticals-961.32% -74.70% -54.02%
Blueprint Medicines -27.70%-64.60%-17.22%

Summary

Recursion Pharmaceuticals beats Blueprint Medicines on 9 of the 17 factors compared between the two stocks.

Get Recursion Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RXRX vs. The Competition

MetricRecursion PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.14B$2.43B$5.53B$9.02B
Dividend YieldN/A1.78%5.22%3.99%
P/E Ratio-2.979.1527.7920.25
Price / Sales36.34680.43426.06119.26
Price / CashN/A21.7726.2128.59
Price / Book2.024.558.045.65
Net Income-$463.66M$31.26M$3.18B$249.15M
7 Day Performance3.95%2.98%2.89%2.91%
1 Month Performance-4.19%3.46%1.67%4.11%
1 Year Performance-28.14%0.77%34.53%20.98%

Recursion Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RXRX
Recursion Pharmaceuticals
1.7586 of 5 stars
$5.26
+1.0%
$7.00
+33.1%
-28.1%$2.14B$58.84M-2.97400
BPMC
Blueprint Medicines
1.5405 of 5 stars
$128.14
+0.0%
$128.06
-0.1%
+14.8%$8.28B$562.12M-51.88640
BBIO
BridgeBio Pharma
4.6879 of 5 stars
$43.03
-4.1%
$58.85
+36.8%
+69.7%$8.17B$221.90M-12.19400
VRNA
Verona Pharma PLC American Depositary Share
2.7874 of 5 stars
$94.57
+0.8%
$101.10
+6.9%
+466.0%$8.05B$42.28M-47.2930Positive News
ROIV
Roivant Sciences
1.5219 of 5 stars
$11.26
-1.1%
$17.50
+55.4%
+1.8%$7.65B$29.05M-45.04860
ELAN
Elanco Animal Health
2.3849 of 5 stars
$14.25
-0.3%
$15.17
+6.4%
+3.0%$7.08B$4.44B19.269,000Analyst Upgrade
RVMD
Revolution Medicines
4.5774 of 5 stars
$36.88
-0.1%
$67.58
+83.3%
-1.4%$6.87B$11.58M-9.22250
LEGN
Legend Biotech
3.1003 of 5 stars
$35.80
+3.4%
$76.20
+112.8%
-23.7%$6.58B$627.24M-60.682,609Positive News
GRFS
Grifols
4.1158 of 5 stars
$8.93
+0.8%
$10.30
+15.3%
+28.9%$6.14B$7.81B7.6323,822News Coverage
Analyst Upgrade
TGTX
TG Therapeutics
3.2919 of 5 stars
$35.98
-2.0%
$40.80
+13.4%
+95.7%$5.71B$329M149.92290
LNTH
Lantheus
4.4551 of 5 stars
$82.20
+0.9%
$130.50
+58.8%
+0.4%$5.69B$1.53B23.35700Positive News

Related Companies and Tools


This page (NASDAQ:RXRX) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners